{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:34:20Z","timestamp":1794018860605,"version":"4.8.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["754658"],"award-info":[{"award-number":["754658"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["754658"],"award-info":[{"award-number":["754658"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["754658"],"award-info":[{"award-number":["754658"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["754658"],"award-info":[{"award-number":["754658"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Clinical development of chimeric antigen receptor (CAR)-T-cell therapy has been enabled by advances in synthetic biology, genetic engineering, clinical-grade manufacturing, and complex logistics to distribute the drug product to treatment sites. A key ambition of the CARAMBA project is to provide clinical proof-of-concept for virus-free CAR gene transfer using advanced <jats:italic>Sleeping Beauty<\/jats:italic> (SB) transposon technology. SB transposition in CAR-T engineering is attractive due to the high rate of stable CAR gene transfer enabled by optimized hyperactive SB100X transposase and transposon combinations, encoded by mRNA and minicircle DNA, respectively, as preferred vector embodiments. This approach bears the potential to facilitate and expedite vector procurement, CAR-T manufacturing and distribution, and the promise to provide a safe, effective, and economically sustainable treatment. As an exemplary and novel target for SB-based CAR-T cells, the CARAMBA consortium has selected the SLAMF7 antigen in multiple myeloma. SLAMF7 CAR-T cells confer potent and consistent anti-myeloma activity in preclinical assays in vitro and in vivo. The CARAMBA clinical trial (Phase-I\/IIA; EudraCT: 2019-001264-30) investigates the feasibility, safety, and anti-myeloma efficacy of autologous SLAMF7 CAR-T cells. CARAMBA is the first clinical trial with virus-free CAR-T cells in Europe, and the first clinical trial that uses advanced SB technology worldwide.<\/jats:p>","DOI":"10.1038\/s41434-021-00254-w","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T01:02:25Z","timestamp":1618275745000},"page":"560-571","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":166,"title":["CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4276-2268","authenticated-orcid":false,"given":"Sabrina","family":"Prommersberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Reiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Beckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Danhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8739-4249","authenticated-orcid":false,"given":"Maximilian","family":"Amberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Quade-Lyssy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-0819","authenticated-orcid":false,"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2280-2202","authenticated-orcid":false,"given":"Michael","family":"Hudecek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0088-2675","authenticated-orcid":false,"given":"Halvard","family":"Bonig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7803-6658","authenticated-orcid":false,"given":"Zolt\u00e1n","family":"Ivics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,13]]},"reference":[{"key":"254_CR1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1073\/pnas.36.6.344","volume":"36","author":"B McClintock","year":"1950","unstructured":"McClintock B. The origin and behavior of mutable loci in maize. Proc Natl Acad Sci USA. 1950;36:344\u201355.","journal-title":"Proc Natl Acad Sci USA"},{"key":"254_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/1759-8753-1-25","volume":"1","author":"Z Ivics","year":"2010","unstructured":"Ivics Z, Izsvak Z. The expanding universe of transposon technologies for gene and cell engineering. Mob DNA. 2010;1:25.","journal-title":"Mob DNA"},{"key":"254_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nmeth.1332","volume":"6","author":"Z Ivics","year":"2009","unstructured":"Ivics Z, Li MA, Mates L, Boeke JD, Nagy A, Bradley A, et al. Transposon-mediated genome manipulation in vertebrates. Nat Methods. 2009;6:415\u201322.","journal-title":"Nat Methods"},{"key":"254_CR4","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0092-8674(00)80436-5","volume":"91","author":"Z Ivics","year":"1997","unstructured":"Ivics Z, Hackett PB, Plasterk RH, Izsvak Z. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell. 1997;91:501\u201310.","journal-title":"Cell"},{"key":"254_CR5","first-page":"18","volume":"52","author":"SA Narayanavari","year":"2017","unstructured":"Narayanavari SA, Chilkunda SS, Ivics Z, Izsvak Z. Sleeping Beauty transposition: from biology to applications. Crit Rev Biochem Mol Biol. 2017;52:18\u201344.","journal-title":"Sleeping Beauty"},{"key":"254_CR6","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1089\/hum.2011.143","volume":"22","author":"Z Ivics","year":"2011","unstructured":"Ivics Z, Izsvak Z. Nonviral gene delivery with the Sleeping Beauty transposon system. Hum Gene Ther. 2011;22:1043\u201351.","journal-title":"Hum Gene Ther"},{"key":"254_CR7","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/mt.2010.2","volume":"18","author":"PB Hackett","year":"2010","unstructured":"Hackett PB, Largaespada DA, Cooper LJN. A transposon and transposase system for human application. Mol Ther. 2010;18:674\u201383.","journal-title":"Mol Ther"},{"key":"254_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2174\/156652311797415827","volume":"11","author":"PB Hackett Jr.","year":"2011","unstructured":"Hackett PB Jr., Aronovich EL, Hunter D, Urness M, Bell JB, Kass SJ, et al. Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies. Curr Gene Ther. 2011;11:341\u20139.","journal-title":"Curr Gene Ther"},{"key":"254_CR9","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/bies.201000027","volume":"32","author":"Z Izsvak","year":"2010","unstructured":"Izsvak Z, Hackett PB, Cooper LJ, Ivics Z. Translating Sleeping Beauty transposition into cellular therapies: victories and challenges. Bioessays. 2010;32:756\u201367.","journal-title":"Bioessays"},{"key":"254_CR10","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1182\/blood-2009-04-210427","volume":"114","author":"T VandenDriessche","year":"2009","unstructured":"VandenDriessche T, Ivics Z, Izsvak Z, Chuah MKL. Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells. Blood. 2009;114:1461\u20138.","journal-title":"Blood"},{"key":"254_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2174\/1566523215666150126121353","volume":"15","author":"P Boehme","year":"2015","unstructured":"Boehme P, Doerner J, Solanki M, Jing L, Zhang W, Ehrhardt A. The Sleeping Beauty transposon vector system for treatment of rare genetic diseases: an unrealized hope? Curr Gene Ther. 2015;15:255\u201365.","journal-title":"Curr Gene Ther"},{"key":"254_CR12","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.gde.2018.06.003","volume":"52","author":"M Hudecek","year":"2018","unstructured":"Hudecek M, Ivics Z. Non-viral therapeutic cell engineering with the Sleeping Beauty transposon system. Curr Opin Genet Dev. 2018;52:100\u20138.","journal-title":"Curr Opin Genet Dev"},{"key":"254_CR13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/10409238.2017.1304354","volume":"52","author":"M Hudecek","year":"2017","unstructured":"Hudecek M, Izsvak Z, Johnen S, Renner M, Thumann G, Ivics Z. Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side. Crit Rev Biochem Mol Biol. 2017;52:355\u201380.","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"254_CR14","doi-asserted-by":"publisher","first-page":"e2000136","DOI":"10.1002\/bies.202000136","volume":"42","author":"M Amberger","year":"2020","unstructured":"Amberger M, Ivics Z. Latest advances for the Sleeping Beauty transposon system: 23 years of insomnia but prettier than ever: refinement and recent innovations of the Sleeping Beauty transposon system enabling novel, nonviral genetic engineering applications. Bioessays. 2020;42:e2000136.","journal-title":"Bioessays"},{"key":"254_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virusres.2007.10.005","volume":"132","author":"ZC Hartman","year":"2008","unstructured":"Hartman ZC, Appledorn DM, Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res. 2008;132:1\u201314.","journal-title":"Virus Res"},{"key":"254_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/75568","volume":"25","author":"SR Yant","year":"2000","unstructured":"Yant SR, Meuse L, Chiu W, Ivics Z, Izsvak Z, Kay MA. Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat. Genet. 2000;25:35\u201341.","journal-title":"Nat. Genet."},{"key":"254_CR17","doi-asserted-by":"publisher","first-page":"10.1128\/microbi","DOI":"10.1128\/microbiolspec.MDNA3-0052-2014","volume":"3","author":"M Salganik","year":"2015","unstructured":"Salganik M, Hirsch ML, Samulski RJ. Adeno-associated virus as a mammalian DNA vector. Microbiol. Spectr. 2015;3. https:\/\/doi.org\/10.1128\/microbiolspec.MDNA3-0052-2014.","journal-title":"Microbiol. Spectr"},{"key":"254_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-1-4939-3271-9_2","volume":"1382","author":"ML Hirsch","year":"2016","unstructured":"Hirsch ML, Wolf SJ, Samulski RJ. Delivering transgenic DNA exceeding the carrying capacity of AAV vectors. Methods Mol Biol. 2016;1382:21\u201339.","journal-title":"Methods Mol Biol"},{"key":"254_CR19","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/sj.gt.3302570","volume":"12","author":"PL Sinn","year":"2005","unstructured":"Sinn PL, Sauter SL, McCray PB Jr. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors-design, biosafety, and production. Gene Ther. 2005;12:1089\u201398.","journal-title":"Gene Ther"},{"key":"254_CR20","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/mt.2009.319","volume":"18","author":"J Matrai","year":"2010","unstructured":"Matrai J, Chuah MK, VandenDriessche T. Recent advances in lentiviral vector development and applications. Mol Ther. 2010;18:477\u201390.","journal-title":"Mol Ther"},{"key":"254_CR21","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ymthe.2003.11.024","volume":"9","author":"H Zayed","year":"2004","unstructured":"Zayed H, Izsvak Z, Walisko O, Ivics Z. Development of hyperactive Sleeping Beauty transposon vectors by mutational analysis. Mol Ther. 2004;9:292\u2013304.","journal-title":"Mol Ther"},{"key":"254_CR22","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1093\/nar\/gks643","volume":"40","author":"M Rostovskaya","year":"2012","unstructured":"Rostovskaya M, Fu J, Obst M, Baer I, Weidlich S, Wang H, et al. Transposon-mediated BAC transgenesis in human ES cells. Nucleic Acids Res. 2012;40:e150.","journal-title":"Nucleic Acids Res"},{"key":"254_CR23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/sj.mt.6300366","volume":"16","author":"O Walisko","year":"2008","unstructured":"Walisko O, Schorn A, Rolfs F, Devaraj A, Miskey C, Izsvak Z, et al. Transcriptional activities of the Sleeping Beauty transposon and shielding its genetic cargo with insulators. Mol Ther. 2008;16:359\u201369.","journal-title":"Mol Ther"},{"key":"254_CR24","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1089\/hum.2007.099","volume":"18","author":"B Moldt","year":"2007","unstructured":"Moldt B, Yant SR, Andersen PR, Kay MA, Mikkelsen JG. Cis-acting gene regulatory activities in the terminal regions of Sleeping Beauty DNA transposon-based vectors. Hum Gene Ther. 2007;18:1193\u2013204.","journal-title":"Hum Gene Ther"},{"key":"254_CR25","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/sj.mt.6300169","volume":"15","author":"Z Ivics","year":"2007","unstructured":"Ivics Z, Katzer A, Stuwe EE, Fiedler D, Knespel S, Izsvak Z. Targeted Sleeping Beauty transposition in human cells. Mol Ther. 2007;15:1137\u201344.","journal-title":"Mol Ther"},{"key":"254_CR26","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.trsl.2012.12.005","volume":"161","author":"PB Hackett","year":"2013","unstructured":"Hackett PB, Largaespada DA, Switzer KC, Cooper LJ. Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy. Transl Res. 2013;161:265\u201383.","journal-title":"Transl Res"},{"key":"254_CR27","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/mt.2016.11","volume":"24","author":"A Gogol-Doring","year":"2016","unstructured":"Gogol-Doring A, Ammar I, Gupta S, Bunse M, Miskey C, Chen W, et al. Genome-wide profiling reveals remarkable parallels between insertion site selection properties of the MLV retrovirus and the piggyBac transposon in primary human CD4(+) T cells. Mol Ther. 2016;24:592\u2013606.","journal-title":"Mol Ther"},{"key":"254_CR28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ymthe.2003.11.009","volume":"9","author":"Z Izsvak","year":"2004","unstructured":"Izsvak Z, Ivics Z. Sleeping Beauty transposition: biology and applications for molecular therapy. Mol Ther. 2004;9:147\u201356.","journal-title":"Mol Ther"},{"key":"254_CR29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0065-2660(05)54009-4","volume":"54","author":"PB Hackett","year":"2005","unstructured":"Hackett PB, Ekker SC, Largaespada DA, McIvor RS. Sleeping Beauty transposon-mediated gene therapy for prolonged expression. Adv Genet. 2005;54:189\u2013232.","journal-title":"Adv Genet"},{"key":"254_CR30","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.coph.2005.04.015","volume":"5","author":"JJ Essner","year":"2005","unstructured":"Essner JJ, McIvor RS, Hackett PB. Awakening gene therapy with Sleeping Beauty transposons. Curr Opin Pharmacol. 2005;5:513\u20139.","journal-title":"Curr Opin Pharmacol"},{"key":"254_CR31","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2174\/156652306778520647","volume":"6","author":"Z Ivics","year":"2006","unstructured":"Ivics Z, Izsvak Z. Transposons for gene therapy! Curr Gene Ther. 2006;6:593\u2013607.","journal-title":"Curr Gene Ther"},{"key":"254_CR32","doi-asserted-by":"publisher","first-page":"R14","DOI":"10.1093\/hmg\/ddr140","volume":"20","author":"EL Aronovich","year":"2011","unstructured":"Aronovich EL, McIvor RS, Hackett PB. The Sleeping Beauty transposon system: a non-viral vector for gene therapy. Hum Mol Genet. 2011;20:R14\u201320.","journal-title":"Hum Mol Genet"},{"key":"254_CR33","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.tig.2017.08.008","volume":"33","author":"P Kebriaei","year":"2017","unstructured":"Kebriaei P, Izsvak Z, Narayanavari SA, Singh H, Ivics Z. Gene therapy with the Sleeping Beauty transposon system. Trends Genet. 2017;33:852\u201370.","journal-title":"Trends Genet"},{"key":"254_CR34","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1172\/JCI86721","volume":"126","author":"P Kebriaei","year":"2016","unstructured":"Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, et al. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Investig. 2016;126:3363\u201376.","journal-title":"J Clin Investig"},{"key":"254_CR35","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1172\/JCI138473","volume":"130","author":"CF Magnani","year":"2020","unstructured":"Magnani CF, Gaipa G, Lussana F, Belotti D, Gritti G, Napolitano S, et al. Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities. J Clin Investig. 2020;130:6021\u201333.","journal-title":"J Clin Investig"},{"key":"254_CR36","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1182\/blood-2009-03-210005","volume":"114","author":"X Xue","year":"2009","unstructured":"Xue X, Huang X, Nodland SE, Mates L, Ma L, Izsvak Z, et al. Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system. Blood. 2009;114:1319\u201330.","journal-title":"Blood"},{"key":"254_CR37","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/ng.343","volume":"41","author":"L Mates","year":"2009","unstructured":"Mates L, Chuah MK, Belay E, Jerchow B, Manoj N, Acosta-Sanchez A, et al. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet. 2009;41:753\u201361.","journal-title":"Nat Genet"},{"key":"254_CR38","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1089\/hum.2017.136","volume":"29","author":"J Clauss","year":"2018","unstructured":"Clauss J, Obenaus M, Miskey C, Ivics Z, Izsvak Z, Uckert W, et al. Efficient non-viral T cell engineering by Sleeping Beauty minicircles diminishing DNA toxicity and miRNAs silencing the endogenous TCR. Hum Gene Ther. 2018;29:569\u201384.","journal-title":"Hum Gene Ther"},{"key":"254_CR39","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/leu.2016.180","volume":"31","author":"R Monjezi","year":"2017","unstructured":"Monjezi R, Miskey C, Gogishvili T, Schleef M, Schmeer M, Einsele H, et al. Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors. Leukemia. 2017;31:186\u201394.","journal-title":"Leukemia"},{"key":"254_CR40","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.ymthe.2018.01.012","volume":"26","author":"M Holstein","year":"2018","unstructured":"Holstein M, Mesa-Nunez C, Miskey C, Almarza E, Poletti V, Schmeer M, et al. Efficient non-viral gene delivery into human hematopoietic stem cells by minicircle Sleeping Beauty transposon vectors. Mol Ther. 2018;26:1137\u201353.","journal-title":"Mol Ther"},{"key":"254_CR41","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1038\/s41587-019-0291-z","volume":"37","author":"I Querques","year":"2019","unstructured":"Querques I, Mades A, Zuliani C, Miskey C, Alb M, Grueso E, et al. A highly soluble Sleeping Beauty transposase improves control of gene insertion. Nat Biotechnol. 2019;37:1502\u201312.","journal-title":"Nat Biotechnol"},{"key":"254_CR42","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1038\/mtna.2013.1","volume":"2","author":"N Sharma","year":"2013","unstructured":"Sharma N, Cai Y, Bak RO, Jakobsen MR, Schroder LD, Mikkelsen JG. Efficient Sleeping Beauty DNA transposition from DNA minicircles. Mol Ther Nucleic Acids. 2013;2:e74.","journal-title":"Mol Ther Nucleic Acids"},{"key":"254_CR43","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/sj.gt.3300540","volume":"4","author":"AM Darquet","year":"1997","unstructured":"Darquet AM, Cameron B, Wils P, Scherman D, Crouzet J. A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Ther. 1997;4:1341\u20139.","journal-title":"Gene Ther"},{"key":"254_CR44","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/gt.2011.215","volume":"20","author":"S Chabot","year":"2013","unstructured":"Chabot S, Orio J, Schmeer M, Schleef M, Golzio M, Teissi\u00e9 J. Minicircle DNA electrotransfer for efficient tissue-targeted gene delivery. Gene Ther. 2013;20:62\u201368.","journal-title":"Gene Ther"},{"key":"254_CR45","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1006\/jmbi.2000.4047","volume":"302","author":"Z Izsvak","year":"2000","unstructured":"Izsvak Z, Ivics Z, Plasterk RH. Sleeping Beauty, a wide host-range transposon vector for genetic transformation in vertebrates. J Mol Biol. 2000;302:93\u2013102.","journal-title":"J Mol Biol"},{"key":"254_CR46","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1582-4934.2007.00038.x","volume":"11","author":"JM Wiehe","year":"2007","unstructured":"Wiehe JM, Ponsaerts P, Rojewski MT, Homann JM, Greiner J, Kronawitter D, et al. mRNA-mediated gene delivery into human progenitor cells promotes highly efficient protein expression. J Cell Mol Med. 2007;11:521\u201330.","journal-title":"J Cell Mol Med"},{"key":"254_CR47","doi-asserted-by":"crossref","unstructured":"Miskey C, Amberger M, Reiser M, Prommersberger S, Beckmann J, Machwirth M, et al. Genomic analyses of SLAMF7 CAR-T cells manufactured by Sleeping Beauty transposon gene transfer for immunotherapy of multiple myeloma. bioRxiv. 2019;675009.","DOI":"10.1101\/675009"},{"key":"254_CR48","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","volume":"130","author":"T Gogishvili","year":"2017","unstructured":"Gogishvili T, Danhof S, Prommersberger S, Rydzek J, Schreder M, Brede C, et al. SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes. Blood. 2017;130:2838\u201347.","journal-title":"Blood"},{"key":"254_CR49","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/978-3-319-42934-2_3","volume":"209","author":"M Hudecek","year":"2016","unstructured":"Hudecek M, Gogishvili T, Monjezi R, Wegner J, Shankar R, Kruesemann C. et al. Minicircle-based engineering of chimeric antigen receptor (CAR) T cells. Recent Results Cancer Res. 2016;209:37\u201350.","journal-title":"Recent Results Cancer Res"},{"key":"254_CR50","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","volume":"118","author":"X Wang","year":"2011","unstructured":"Wang X, Chang WC, Wong CW, Colcher D, Sherman M, Ostberg JR, et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood. 2011;118:1255\u201363.","journal-title":"Blood"},{"key":"254_CR51","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00432-020-03323-6","volume":"147","author":"D Hose","year":"2021","unstructured":"Hose D, Schreder M, Hefner J, Bittrich M, Danhof S, Strifler S, et al. Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers. J Cancer Res Clin Oncol. 2021;147:205\u201312.","journal-title":"J Cancer Res Clin Oncol"},{"key":"254_CR52","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726\u201337.","journal-title":"N Engl J Med"},{"key":"254_CR53","doi-asserted-by":"crossref","unstructured":"Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128:1688\u2013700.","DOI":"10.1182\/blood-2016-04-711903"},{"key":"254_CR54","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1182\/blood.2019000050","volume":"134","author":"MJ Pont","year":"2019","unstructured":"Pont MJ, Hill T, Cole GO, Abbott JJ, Kelliher J, Salter AI, et al. Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019;134:1585\u201397.","journal-title":"Blood"},{"key":"254_CR55","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/leu.2015.247","volume":"30","author":"D Sommermeyer","year":"2016","unstructured":"Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2016;30:492\u2013500.","journal-title":"Leukemia"},{"key":"254_CR56","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","volume":"14","author":"ED Hsi","year":"2008","unstructured":"Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14:2775\u201384.","journal-title":"Clin Cancer Res"},{"key":"254_CR57","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","volume":"112","author":"YT Tai","year":"2008","unstructured":"Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112:1329\u201337.","journal-title":"Blood"},{"key":"254_CR58","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/nar\/gkv1464","volume":"44","author":"M Loperfido","year":"2016","unstructured":"Loperfido M, Jarmin S, Dastidar S, Di Matteo M, Perini I, Moore M, et al. piggyBac transposons expressing full-length human dystrophin enable genetic correction of dystrophic mesoangioblasts. Nucleic Acids Res. 2016;44:744\u201360.","journal-title":"Nucleic Acids Res"},{"key":"254_CR59","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar OU, O\u2019Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr., et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44:380\u201390.","journal-title":"Immunity"},{"key":"254_CR60","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000492146","volume":"140","author":"Q Zhong","year":"2018","unstructured":"Zhong Q, Zhu YM, Zheng LL, Shen HJ, Ou RM, Liu Z, et al. Chimeric antigen receptor-T cells with 4-1BB co-stimulatory domain present a superior treatment outcome than those with CD28 domain based on bioinformatics. Acta Haematol. 2018;140:131\u201340.","journal-title":"Acta Haematol"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00254-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00254-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00254-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T07:08:16Z","timestamp":1632208096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00254-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,13]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["254"],"URL":"https:\/\/doi.org\/10.1038\/s41434-021-00254-w","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,13]]},"assertion":[{"value":"15 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MH and ZI are co-inventors on patents relating to <i>Sleeping Beauty<\/i> transposon technology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}